ArticleJournal of virology2026
TPPS4 inhibits PEDV by stabilizing viral RNA G-quadruplex and promoting ER stress: a transfer-learning-driven discovery.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Porcine epidemic diarrhea virus (PEDV) is a devastating enteric pathogen that causes substantial economic losses in the global swine industry. While PEDV inhibitors offer a promising alternative to compensate for vaccine evasion caused by viral mutations, their development is bottlenecked by poorly defined antiviral targets and limited compound libraries. Here, we developed a transfer learning framework to accelerate the discovery of anti-PEDV agents by leveraging data from human-associated coronaviruses. Transfer learning-based prediction identified Hemin as a promising PEDV inhibitor, while its analog TPPS4 exhibited potent antiviral activity with EC IMPORTANCE: Veterinary antiviral discovery is hampered by limited bioactivity data and poorly defined targets. To address this, we developed a cross-species transfer learning pipeline to predict anti-PEDV agents. We identified TPPS4 as a potent anti-PEDV compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.